|1||Not yet recruiting||
DNA Single Nucleotide Polymorphisms as Predictors of Toxicity
Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial
|3||Active, not recruiting||
Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma
Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer
Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma
† Study has passed its completion date and status has not been verified in more than two years.